[S02DA03, antipyrine, The metabolism of Antipyrine can be increased when combined with Cyproterone acetate.]
[G03XB02, ulipristal, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Ulipristal.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Streptokinase.]
[J01CA16, sulbenicillin, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Sulbenicillin.]
[J01EC02, sulfadiazine, The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Cyproterone acetate.]
[J01EC01, sulfamethoxazole, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Cyproterone acetate.]
[M04AB02, sulfinpyrazone, The metabolism of Cyproterone acetate can be increased when combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Cyproterone acetate.]
[N03AX03, sulthiame, The metabolism of Cyproterone acetate can be increased when combined with Sulthiame.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be decreased when used in combination with Cyproterone acetate.]
[A10BC01, glymidine, The therapeutic efficacy of Glymidine can be decreased when used in combination with Cyproterone acetate.]
[N06DA01, tacrine, The metabolism of Tacrine can be increased when combined with Cyproterone acetate.]
[J01CA15, talampicillin, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Talampicillin.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be increased when combined with Cyproterone acetate.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Cyproterone acetate.]
[B01AE07, dabigatran etexilate, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Dabigatran etexilate.]
[G03BA03, testosterone, The metabolism of Cyproterone acetate can be increased when combined with Testosterone.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Cyproterone acetate is combined with Tetracaine.]
[S03AA02, tetracycline, The serum concentration of Cyproterone acetate can be decreased when it is combined with Tetracycline.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Cyproterone acetate.]
[L04AX02, thalidomide, Cyproterone acetate may increase the thrombogenic activities of Thalidomide.]
[R03DA07, theobromine, The metabolism of Theobromine can be increased when combined with Cyproterone acetate.]
[R03DA04, theophylline, Cyproterone acetate may decrease the excretion rate of Theophylline which could result in a higher serum level.]
[P02CA02, thiabendazole, The metabolism of Thiabendazole can be increased when combined with Cyproterone acetate.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be decreased when combined with Cyproterone acetate.]
[N05CA19, thiopental, The metabolism of Cyproterone acetate can be increased when combined with Thiopental.]
[N05AF04, thiothixene, The metabolism of Thiothixene can be increased when combined with Cyproterone acetate.]
[J01CA13, ticarcillin, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Ticarcillin.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be decreased when used in combination with Cyproterone acetate.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Cyproterone acetate.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Cyproterone acetate.]
[B02AA02, tranexamic acid, Cyproterone acetate may increase the thrombogenic activities of Tranexamic acid.]
[L01XF01, tretinoin, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Tretinoin.]
[S01BA05, triamcinolone, The serum concentration of Triamcinolone can be increased when it is combined with Cyproterone acetate.]
[C03DB02, triamterene, The metabolism of Triamterene can be increased when combined with Cyproterone acetate.]
[N05AB06, trifluoperazine, The metabolism of Trifluoperazine can be increased when combined with Cyproterone acetate.]
[S01AD02, trifluridine, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Trifluridine.]
[D07AC02, fluclorolone, The serum concentration of Fluclorolone can be increased when it is combined with Cyproterone acetate.]
[R03BA07, mometasone, The serum concentration of Mometasone can be increased when it is combined with Cyproterone acetate.]
[N03AC02, trimethadione, The metabolism of Cyproterone acetate can be increased when combined with Trimethadione.]
[J01FA08, troleandomycin, The metabolism of Cyproterone acetate can be decreased when combined with Troleandomycin.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Cyproterone acetate.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be decreased when combined with Cyproterone acetate.]
[A10BH05, linagliptin, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Cyproterone acetate.]
[J05AP03, boceprevir, The serum concentration of Cyproterone acetate can be increased when it is combined with Boceprevir.]
[J05AP02, telaprevir, The serum concentration of Cyproterone acetate can be decreased when it is combined with Telaprevir.]
[B01AD04, urokinase, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Urokinase.]
[N03AX21, ezogabine, The metabolism of Cyproterone acetate can be increased when combined with Ezogabine.]
[B01AF01, rivaroxaban, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Rivaroxaban.]
[B01AC24, ticagrelor, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Ticagrelor.]
[C08DA01, verapamil, The metabolism of Verapamil can be increased when combined with Cyproterone acetate.]
[N06AX09, viloxazine, The metabolism of Cyproterone acetate can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Vinblastine can be decreased when combined with Cyproterone acetate.]
[L01CA02, vincristine, The metabolism of Vincristine can be decreased when combined with Cyproterone acetate.]
[L01CA03, vindesine, The metabolism of Vindesine can be decreased when combined with Cyproterone acetate.]
[S01XA02, vitamin A, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Vitamin A.]
[A11HA03, vitamin E, The metabolism of Cyproterone acetate can be increased when combined with Vitamin E.]
[B01AA03, warfarin, The metabolism of Warfarin can be increased when combined with Cyproterone acetate.]
[N05AF05, zuclopenthixol, The metabolism of Zuclopenthixol can be decreased when combined with Cyproterone acetate.]
[J05AE02, indinavir, The metabolism of Cyproterone acetate can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, The metabolism of Cyproterone acetate can be increased when combined with Levetiracetam.]
[L01EC01, vemurafenib, The metabolism of Vemurafenib can be decreased when combined with Cyproterone acetate.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be decreased when combined with Cyproterone acetate.]
[L01ED01, crizotinib, The metabolism of Crizotinib can be decreased when combined with Cyproterone acetate.]
[B01AE01, desirudin, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Lepirudin.]
[N05AE04, ziprasidone, The metabolism of Cyproterone acetate can be decreased when combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Drospirenone can be decreased when combined with Cyproterone acetate.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be decreased when combined with Cyproterone acetate.]
[J02AC03, voriconazole, The metabolism of Cyproterone acetate can be decreased when combined with Voriconazole.]
[L01EK01, axitinib, The metabolism of Axitinib can be increased when combined with Cyproterone acetate.]
[H02AB11, prednylidene, The serum concentration of Prednylidene can be increased when it is combined with Cyproterone acetate.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Cyproterone acetate.]
[L04AX01, azathioprine, The metabolism of Azathioprine can be increased when combined with Cyproterone acetate.]
[J01CA09, azlocillin, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Azlocillin.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Cyproterone acetate.]
[A08AA11, lorcaserin, The metabolism of Lorcaserin can be increased when combined with Cyproterone acetate.]
[V03AX03, cobicistat, The serum concentration of Cyproterone acetate can be decreased when it is combined with Cobicistat.]
[J05AJ02, elvitegravir, The serum concentration of Cyproterone acetate can be decreased when it is combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Cyproterone acetate can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be decreased when combined with Cyproterone acetate.]
[B01AX01, defibrotide, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Defibrotide.]
[H02AA01, aldosterone, The serum concentration of Aldosterone can be increased when it is combined with Cyproterone acetate.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be decreased when combined with Cyproterone acetate.]
[N05CA04, barbital, The metabolism of Cyproterone acetate can be increased when combined with Barbital.]
[J05AE04, nelfinavir, The metabolism of Cyproterone acetate can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The metabolism of Bendamustine can be increased when combined with Cyproterone acetate.]
[N04BD02, rasagiline, The metabolism of Rasagiline can be increased when combined with Cyproterone acetate.]
[N03AX22, perampanel, The metabolism of Perampanel can be increased when combined with Cyproterone acetate.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Cyproterone acetate.]
[N02CC03, zolmitriptan, The metabolism of Zolmitriptan can be increased when combined with Cyproterone acetate.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Cyproterone acetate.]
[B01AF02, apixaban, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Apixaban.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be decreased when combined with Cyproterone acetate.]
[A10BH04, alogliptin, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Cyproterone acetate.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Cyproterone acetate can be increased when combined with Glycerol phenylbutyrate.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be increased when combined with Cyproterone acetate.]
[A10BK02, canagliflozin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Cyproterone acetate.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Cyproterone acetate.]
[R02AD01, benzocaine, The metabolism of Benzocaine can be increased when combined with Cyproterone acetate.]
[A10BX05, pramlintide, The therapeutic efficacy of Pramlintide can be decreased when used in combination with Cyproterone acetate.]
[C10AC04, colesevelam, Colesevelam can cause a decrease in the absorption of Cyproterone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AA18, everolimus, The metabolism of Everolimus can be decreased when combined with Cyproterone acetate.]
[L01EC02, dabrafenib, The serum concentration of Cyproterone acetate can be decreased when it is combined with Dabrafenib.]
[P03AX06, benzyl alcohol, The metabolism of Benzyl alcohol can be increased when combined with Cyproterone acetate.]
[A10BJ03, lixisenatide, The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Cyproterone acetate.]
[A05AA03, cholic acid, The therapeutic efficacy of Cholic Acid can be decreased when used in combination with Cyproterone acetate.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Cyproterone acetate.]
[N03AF04, eslicarbazepine, The metabolism of Cyproterone acetate can be increased when combined with Eslicarbazepine.]
[J05AP05, simeprevir, The metabolism of Cyproterone acetate can be decreased when combined with Simeprevir.]
[N03AG04, vigabatrin, The metabolism of Cyproterone acetate can be increased when combined with Vigabatrin.]
[A10BK01, dapagliflozin, The metabolism of Dapagliflozin can be increased when combined with Cyproterone acetate.]
[N05CH03, tasimelteon, The metabolism of Tasimelteon can be increased when combined with Cyproterone acetate.]
[A16AA07, metreleptin, The metabolism of Cyproterone acetate can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Apremilast can be increased when combined with Cyproterone acetate.]
[L02BG02, formestane, The metabolism of Cyproterone acetate can be increased when combined with Formestane.]
[S03BA03, betamethasone, The serum concentration of Betamethasone can be increased when it is combined with Cyproterone acetate.]
[S01ED02, betaxolol, The metabolism of Betaxolol can be increased when combined with Cyproterone acetate.]
[B01AE03, argatroban, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Argatroban.]
[A10BJ04, albiglutide, The therapeutic efficacy of Albiglutide can be decreased when used in combination with Cyproterone acetate.]
[L04AC11, siltuximab, The metabolism of Cyproterone acetate can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Ceritinib can be decreased when combined with Cyproterone acetate.]
[B01AC26, vorapaxar, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Vorapaxar.]
[B01AA07, acenocoumarol, The metabolism of Acenocoumarol can be increased when combined with Cyproterone acetate.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be decreased when combined with Cyproterone acetate.]
[A10BK03, empagliflozin, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Cyproterone acetate.]
[N05CM19, suvorexant, The metabolism of Suvorexant can be decreased when combined with Cyproterone acetate.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Cyproterone acetate.]
[J01XA05, oritavancin, The metabolism of Cyproterone acetate can be increased when combined with Oritavancin.]
[A10BJ05, dulaglutide, The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Cyproterone acetate.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be increased when combined with Cyproterone acetate.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be decreased when combined with Cyproterone acetate.]
[L01XK01, olaparib, The metabolism of Olaparib can be decreased when combined with Cyproterone acetate.]
[B01AA01, dicumarol, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Dicoumarol.]
[B01AF03, edoxaban, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Edoxaban.]
[N06AX11, mirtazapine, The metabolism of Mirtazapine can be increased when combined with Cyproterone acetate.]
[B06AC04, C1 esterase inhibitor (recombinant), The risk or severity of thromboembolism can be increased when Cyproterone acetate is combined with Conestat alfa.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be decreased when combined with Cyproterone acetate.]
[L01XH03, panobinostat, The metabolism of Panobinostat can be decreased when combined with Cyproterone acetate.]
[N02BE01, acetaminophen, The metabolism of Acetaminophen can be increased when combined with Cyproterone acetate.]
[B01AA11, tioclomarol, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Tioclomarol.]
[J05AP06, asunaprevir, The serum concentration of Cyproterone acetate can be decreased when it is combined with Asunaprevir.]
[B01AC25, cangrelor, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Cangrelor.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be decreased when combined with Cyproterone acetate.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Flibanserin.]
[A10BF01, acarbose, The therapeutic efficacy of Acarbose can be decreased when used in combination with Cyproterone acetate.]
[S01EC01, acetazolamide, The metabolism of Cyproterone acetate can be increased when combined with Acetazolamide.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Cyproterone acetate.]
[D05BB02, acitretin, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Acitretin.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Cyproterone acetate.]
[J02AC05, isavuconazole, The metabolism of Cyproterone acetate can be decreased when combined with Isavuconazole.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be decreased when combined with Cyproterone acetate.]
[J05AF13, tenofovir alafenamide, The metabolism of Tenofovir alafenamide can be decreased when combined with Cyproterone acetate.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be decreased when combined with Cyproterone acetate.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be decreased when combined with Cyproterone acetate.]
[V03AB35, sugammadex, The serum concentration of Cyproterone acetate can be decreased when it is combined with Sugammadex.]
[L01ED03, alectinib, The metabolism of Alectinib can be decreased when combined with Cyproterone acetate.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Cyproterone acetate.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Cyproterone acetate.]
[M04AB05, lesinurad, The metabolism of Cyproterone acetate can be increased when combined with Lesinurad.]
[N05CA05, aprobarbital, The metabolism of Cyproterone acetate can be increased when combined with Aprobarbital.]
[N03AX23, brivaracetam, The metabolism of Cyproterone acetate can be increased when combined with Brivaracetam.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be decreased when combined with Cyproterone acetate.]
[N05BA08, bromazepam, The metabolism of Bromazepam can be increased when combined with Cyproterone acetate.]
[N04BC01, bromocriptine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Cyproterone acetate.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be decreased when combined with Cyproterone acetate.]
[A05AA04, obeticholic acid, The therapeutic efficacy of Obeticholic acid can be decreased when used in combination with Cyproterone acetate.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Cyproterone acetate is combined with Bupivacaine.]
[L01AB01, busulfan, The metabolism of Busulfan can be decreased when combined with Cyproterone acetate.]
[S01GX07, azelastine, The metabolism of Azelastine can be increased when combined with Cyproterone acetate.]
[J01CE04, azidocillin, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Azidocillin.]
[L01XK03, rucaparib, The metabolism of Rucaparib can be increased when combined with Cyproterone acetate.]
[S01AA26, azithromycin, The metabolism of Azithromycin can be decreased when combined with Cyproterone acetate.]
[J01CA06, bacampicillin, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Bacampicillin.]
[L01EF02, ribociclib, The metabolism of Cyproterone acetate can be decreased when combined with Ribociclib.]
[R03DA08, bamifylline, The metabolism of Bamifylline can be increased when combined with Cyproterone acetate.]
[N02BF02, pregabalin, The metabolism of Cyproterone acetate can be increased when combined with Pregabalin.]
[N03AX30, beclamide, The metabolism of Cyproterone acetate can be increased when combined with Beclamide.]
[N06BC01, caffeine, The metabolism of Caffeine can be increased when combined with Cyproterone acetate.]
[A10BX06, benfluorex, The therapeutic efficacy of Benfluorex can be decreased when used in combination with Cyproterone acetate.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Cyproterone acetate is combined with Oxybuprocaine.]
[D05AX03, calcitriol, The metabolism of Cyproterone acetate can be increased when combined with Calcitriol.]
[J05AE09, tipranavir, The metabolism of Cyproterone acetate can be decreased when combined with Tipranavir.]
[L01EX10, midostaurin, The metabolism of Cyproterone acetate can be decreased when combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Cyproterone acetate.]
[L04AC14, sarilumab, The metabolism of Cyproterone acetate can be increased when combined with Sarilumab.]
[B01AF04, betrixaban, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Betrixaban.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be increased when combined with Cyproterone acetate.]
[L01EH02, neratinib, The metabolism of Neratinib can be decreased when combined with Cyproterone acetate.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Cyproterone acetate.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be decreased when combined with Cyproterone acetate.]
[J05AG03, efavirenz, The metabolism of Efavirenz can be increased when combined with Cyproterone acetate.]
[R03BA02, budesonide, The serum concentration of Budesonide can be increased when it is combined with Cyproterone acetate.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be decreased when combined with Cyproterone acetate.]
[A10BJ06, semaglutide, The therapeutic efficacy of Semaglutide can be decreased when used in combination with Cyproterone acetate.]
[N01BX04, capsaicin, The metabolism of Capsaicin can be increased when combined with Cyproterone acetate.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Cyproterone acetate.]
[L02BB05, apalutamide, The metabolism of Cyproterone acetate can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The serum concentration of Cyproterone acetate can be decreased when it is combined with Carbamazepine.]
[J01CA03, carbenicillin, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Carbenicillin.]
[C07AG02, carvedilol, The metabolism of Carvedilol can be increased when combined with Cyproterone acetate.]
[N03AX24, cannabidiol, The metabolism of Cyproterone acetate can be increased when combined with Cannabidiol.]
[L01EE03, binimetinib, The metabolism of Binimetinib can be increased when combined with Cyproterone acetate.]
[L01XX62, ivosidenib, The metabolism of Cyproterone acetate can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Cyproterone acetate can be decreased when combined with Stiripentol.]
[J05AX24, tecovirimat, The metabolism of Cyproterone acetate can be increased when combined with Tecovirimat.]
[J01AA13, eravacycline, The serum concentration of Cyproterone acetate can be decreased when it is combined with Eravacycline.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be decreased when combined with Cyproterone acetate.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Cyproterone acetate.]
[J01AA14, sarecycline, The serum concentration of Cyproterone acetate can be decreased when it is combined with Sarecycline.]
[J01AA15, omadacycline, The serum concentration of Cyproterone acetate can be decreased when it is combined with Omadacycline.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be decreased when used in combination with Cyproterone acetate.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Cyproterone acetate is combined with Chloroprocaine.]
[R03DA02, oxtriphylline, The metabolism of Oxtriphylline can be increased when combined with Cyproterone acetate.]
[L01ED05, lorlatinib, The metabolism of Cyproterone acetate can be increased when combined with Lorlatinib.]
[L01AD01, carmustine, The metabolism of Carmustine can be increased when combined with Cyproterone acetate.]
[L01EX13, gilteritinib, The metabolism of Gilteritinib can be decreased when combined with Cyproterone acetate.]
[A06AX05, prucalopride, The serum concentration of Cyproterone acetate can be decreased when it is combined with Prucalopride.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Cyproterone acetate.]
[P02BX04, triclabendazole, The metabolism of Triclabendazole can be increased when combined with Cyproterone acetate.]
[N06AX27, esketamine, The metabolism of Cyproterone acetate can be increased when combined with Esketamine.]
[L04AA42, siponimod, The metabolism of Siponimod can be decreased when combined with Cyproterone acetate.]
[J01FA09, clarithromycin, The metabolism of Cyproterone acetate can be decreased when combined with Clarithromycin.]
[N06AX29, brexanolone, The metabolism of Cyproterone acetate can be increased when combined with Brexanolone.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Cyproterone acetate.]
[N05BA09, clobazam, The serum concentration of Cyproterone acetate can be decreased when it is combined with Clobazam.]
[J01AA11, clomocycline, The serum concentration of Cyproterone acetate can be decreased when it is combined with Clomocycline.]
[H02AB14, cloprednol, The serum concentration of Cloprednol can be increased when it is combined with Cyproterone acetate.]
[V03AE02, sevelamer, Sevelamer can cause a decrease in the absorption of Cyproterone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H02AB17, cortivazol, The serum concentration of Cortivazol can be increased when it is combined with Cyproterone acetate.]
[L01EM03, alpelisib, The metabolism of Alpelisib can be decreased when combined with Cyproterone acetate.]
[J01CF03, methicillin, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Meticillin.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be decreased when combined with Cyproterone acetate.]
[M03BX08, cyclobenzaprine, The metabolism of Cyclobenzaprine can be increased when combined with Cyproterone acetate.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be decreased when combined with Cyproterone acetate.]
[N07XX11, pitolisant, The serum concentration of Cyproterone acetate can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Pretomanid can be decreased when combined with Cyproterone acetate.]
[J01XX12, lefamulin, The metabolism of Lefamulin can be decreased when combined with Cyproterone acetate.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be increased when combined with Cyproterone acetate.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Cyproterone acetate.]
[S01AA13, fusidic acid, The metabolism of Cyproterone acetate can be decreased when combined with Fusidic acid.]
[B06AC01, C1 esterase inhibitor (human), The risk or severity of thromboembolism can be increased when Cyproterone acetate is combined with Human C1-esterase inhibitor.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be decreased when used in combination with Cyproterone acetate.]
[J01DB01, cephalexin, The metabolism of Cephalexin can be decreased when combined with Cyproterone acetate.]
[J01DB09, cephradine, The metabolism of Cyproterone acetate can be increased when combined with Cefradine.]
[H02AB13, deflazacort, The serum concentration of Deflazacort can be increased when it is combined with Cyproterone acetate.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Cyproterone acetate.]
[B06AX03, voxelotor, The serum concentration of Voxelotor can be increased when it is combined with Cyproterone acetate.]
[N03AX25, cenobamate, The serum concentration of Cyproterone acetate can be decreased when it is combined with Cenobamate.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Cyproterone acetate.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be decreased when combined with Cyproterone acetate.]
[J05AE05, amprenavir, The metabolism of Cyproterone acetate can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The metabolism of Frovatriptan can be increased when combined with Cyproterone acetate.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be increased when combined with Cyproterone acetate.]
[M01AH02, rofecoxib, The metabolism of Rofecoxib can be increased when combined with Cyproterone acetate.]
[L01XF03, bexarotene, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Bexarotene.]
[C08CA16, clevidipine, The metabolism of Cyproterone acetate can be increased when combined with Clevidipine.]
[C01BD07, dronedarone, The metabolism of Dronedarone can be decreased when combined with Cyproterone acetate.]
[N03AG02, dipropylacetamide, The metabolism of Cyproterone acetate can be increased when combined with Valpromide.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Cyproterone acetate.]
[D07XB03, fluprednidene, The serum concentration of Fluprednidene can be increased when it is combined with Cyproterone acetate.]
[B01AE02, lepirudin, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Lepirudin.]
[N05CM02, chlormethiazole, The metabolism of Cyproterone acetate can be increased when combined with Clomethiazole.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Cyproterone acetate is combined with Dyclonine.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Cyproterone acetate.]
[R06AX22, ebastine, The metabolism of Ebastine can be decreased when combined with Cyproterone acetate.]
[L04AC19, satralizumab, The serum concentration of Cyproterone acetate can be decreased when it is combined with Satralizumab.]
[L01EX23, pralsetinib, The metabolism of Cyproterone acetate can be increased when combined with Pralsetinib.]
[N05AA01, chlorpromazine, The metabolism of Chlorpromazine can be increased when combined with Cyproterone acetate.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Cyproterone acetate.]
[M03BB03, chlorzoxazone, The metabolism of Chlorzoxazone can be increased when combined with Cyproterone acetate.]
[C10AC01, cholestyramine resin, Cholestyramine can cause a decrease in the absorption of Cyproterone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N06BX18, vinpocetine, The metabolism of Cyproterone acetate can be increased when combined with Vinpocetine.]
[B06AC06, berotralstat, The metabolism of Cyproterone acetate can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Cyproterone acetate can be decreased when combined with Lonafarnib.]
[P03AX07, abametapir, The serum concentration of Cyproterone acetate can be increased when it is combined with Abametapir.]
[N03AX10, felbamate, The metabolism of Cyproterone acetate can be increased when combined with Felbamate.]
[N06BA10, fenethylline, The metabolism of Fenethylline can be increased when combined with Cyproterone acetate.]
[R03BA03, flunisolide, The serum concentration of Flunisolide can be increased when it is combined with Cyproterone acetate.]
[S02BA08, fluocinolone acetonide, The serum concentration of Fluocinolone acetonide can be increased when it is combined with Cyproterone acetate.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be decreased when used in combination with Cyproterone acetate.]
[N02BF01, gabapentin, The metabolism of Cyproterone acetate can be increased when combined with Gabapentin.]
[N07CA02, cinnarizine, The metabolism of Cinnarizine can be increased when combined with Cyproterone acetate.]
[L01XX73, sotorasib, The serum concentration of Cyproterone acetate can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be decreased when combined with Cyproterone acetate.]
[S03AA07, ciprofloxacin, The metabolism of Cyproterone acetate can be decreased when combined with Ciprofloxacin.]
[V09IX16, piflufolastat F-18, Cyproterone acetate may decrease effectiveness of Piflufolastat F 18 as a diagnostic agent.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Cyproterone acetate.]
[P01CA03, fexinidazole, The metabolism of Fexinidazole can be increased when combined with Cyproterone acetate.]
[L01XX74, belzutifan, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Belzutifan.]
[L01EB10, mobocertinib, The serum concentration of Cyproterone acetate can be decreased when it is combined with Mobocertinib.]
[M01AG01, mefenamic acid, The metabolism of Mefenamic acid can be increased when combined with Cyproterone acetate.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be decreased when used in combination with Cyproterone acetate.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be decreased when used in combination with Cyproterone acetate.]
[N06AX25, St. John's wort extract, The metabolism of Cyproterone acetate can be increased when combined with St. John's Wort.]
[V09IX14, gallium GA-68 gozetotide, Cyproterone acetate may increase effectiveness of Gallium Ga-68 gozetotide as a diagnostic agent.]
[B01AD11, tenecteplase, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Tenecteplase.]
[C10AB01, clofibrate, The metabolism of Cyproterone acetate can be increased when combined with Clofibrate.]
[B06AX04, mitapivat, The metabolism of Cyproterone acetate can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, The metabolism of Levobupivacaine can be increased when combined with Cyproterone acetate.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be increased when combined with Cyproterone acetate.]
[N03AE01, clonazepam, The metabolism of Cyproterone acetate can be increased when combined with Clonazepam.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Cyproterone acetate is combined with Clonidine.]
[C01EB24, mavacamten, The serum concentration of Cyproterone acetate can be decreased when it is combined with Mavacamten.]
[A10BX16, tirzepatide, Tirzepatide can cause a decrease in the absorption of Cyproterone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A04AA01, ondansetron, The metabolism of Ondansetron can be increased when combined with Cyproterone acetate.]
[J01CF02, cloxacillin, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Cloxacillin.]
[N05AH02, clozapine, The metabolism of Clozapine can be increased when combined with Cyproterone acetate.]
[A10BX01, guar gum, The therapeutic efficacy of Guar gum can be decreased when used in combination with Cyproterone acetate.]
[A10BK06, sotagliflozin, The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Cyproterone acetate.]
[H01AC08, somatrogon, The metabolism of Cyproterone acetate can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Cyproterone acetate is combined with Cocaine.]
[M09AX11, palovarotene, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Palovarotene.]
[J01CA18, hetacillin, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Hetacillin.]
[M04AC01, colchicine, The metabolism of Colchicine can be decreased when combined with Cyproterone acetate.]
[C10AC02, colestipol, Colestipol can cause a decrease in the absorption of Cyproterone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AA13, leflunomide, The metabolism of Leflunomide can be increased when combined with Cyproterone acetate.]
[C04AX28, ifenprodil, The metabolism of Cyproterone acetate can be increased when combined with Ifenprodil.]
[A10BX03, nateglinide, The therapeutic efficacy of Nateglinide can be decreased when used in combination with Cyproterone acetate.]
[H01AC03, mecasermin, The therapeutic efficacy of Mecasermin can be decreased when used in combination with Cyproterone acetate.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Cyproterone acetate.]
[J01FA15, telithromycin, The metabolism of Cyproterone acetate can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The serum concentration of Ciclesonide can be increased when it is combined with Cyproterone acetate.]
[J02AC02, itraconazole, The metabolism of Cyproterone acetate can be decreased when combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Bemiparin.]
[S01AD03, acyclovir, The metabolism of Acyclovir can be increased when combined with Cyproterone acetate.]
[L01EA01, imatinib, The metabolism of Imatinib can be increased when combined with Cyproterone acetate.]
[J02AC04, posaconazole, The metabolism of Cyproterone acetate can be decreased when combined with Posaconazole.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cyproterone acetate.]
[N03AX09, lamotrigine, The metabolism of Cyproterone acetate can be increased when combined with Lamotrigine.]
[S01BA03, cortisone, The serum concentration of Cortisone can be increased when it is combined with Cyproterone acetate.]
[N07BC04, lofexidine, The metabolism of Lofexidine can be increased when combined with Cyproterone acetate.]
[S01AE04, lomefloxacin, The metabolism of Lomefloxacin can be increased when combined with Cyproterone acetate.]
[H02AB15, meprednisone, The serum concentration of Meprednisone can be increased when it is combined with Cyproterone acetate.]
[J01CA14, methampicillin, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Metampicillin.]
[A10BF02, miglitol, The therapeutic efficacy of Miglitol can be decreased when used in combination with Cyproterone acetate.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Cyproterone acetate.]
[S01XA18, cyclosporine, The metabolism of Cyclosporine can be decreased when combined with Cyproterone acetate.]
[N06BA07, modafinil, The metabolism of Cyproterone acetate can be increased when combined with Modafinil.]
[C10AA07, rosuvastatin, Rosuvastatin may decrease the excretion rate of Cyproterone acetate which could result in a higher serum level.]
[C03XA02, conivaptan, The metabolism of Cyproterone acetate can be decreased when combined with Conivaptan.]
[J05AF10, entecavir, The metabolism of Entecavir can be increased when combined with Cyproterone acetate.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Cyproterone acetate.]
[M01AH05, etoricoxib, The metabolism of Etoricoxib can be increased when combined with Cyproterone acetate.]
[L01AX04, dacarbazine, The metabolism of Dacarbazine can be increased when combined with Cyproterone acetate.]
[G03XA01, danazol, The metabolism of Cyproterone acetate can be decreased when combined with Danazol.]
[M01AX01, nabumetone, The metabolism of Nabumetone can be increased when combined with Cyproterone acetate.]
[J01AA01, demeclocycline, The serum concentration of Cyproterone acetate can be decreased when it is combined with Demeclocycline.]
[N06AX06, nefazodone, The metabolism of Cyproterone acetate can be decreased when combined with Nefazodone.]
[N03AG06, tiagabine, The metabolism of Cyproterone acetate can be increased when combined with Tiagabine.]
[C01CA23, theodrenaline, The metabolism of Theodrenaline can be increased when combined with Cyproterone acetate.]
[B01AX05, fondaparinux, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Fondaparinux.]
[D07XC02, desoximetasone, The serum concentration of Desoximetasone can be increased when it is combined with Cyproterone acetate.]
[H02AA03, desoxycorticosterone, The serum concentration of Desoxycortone can be increased when it is combined with Cyproterone acetate.]
[N03AF02, oxcarbazepine, The metabolism of Cyproterone acetate can be increased when combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The serum concentration of Dexamethasone can be increased when it is combined with Cyproterone acetate.]
[A08AA04, dexfenfluramine, The metabolism of Dexfenfluramine can be increased when combined with Cyproterone acetate.]
[N03AC01, paramethadione, The metabolism of Cyproterone acetate can be increased when combined with Paramethadione.]
[N06AB05, paroxetine, The metabolism of Paroxetine can be increased when combined with Cyproterone acetate.]
[B01AC04, clopidogrel, The metabolism of Clopidogrel can be increased when combined with Cyproterone acetate.]
[C04AD01, pentifylline, The metabolism of Pentifylline can be increased when combined with Cyproterone acetate.]
[N05BA01, diazepam, The metabolism of Cyproterone acetate can be increased when combined with Diazepam.]
[N03AX07, phenacemide, The metabolism of Cyproterone acetate can be increased when combined with Phenacemide.]
[J01CE05, phenethicillin, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Pheneticillin.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Cyproterone acetate is combined with Phenol.]
[N03AD02, phensuximide, The metabolism of Cyproterone acetate can be increased when combined with Phensuximide.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Cyproterone acetate is combined with Cinchocaine.]
[S01BC03, diclofenac, The metabolism of Diclofenac can be increased when combined with Cyproterone acetate.]
[J01CF01, dicloxacillin, The metabolism of Cyproterone acetate can be increased when combined with Dicloxacillin.]
[A10BG03, pioglitazone, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Cyproterone acetate.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be decreased when combined with Cyproterone acetate.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be increased when combined with Cyproterone acetate.]
[C08CA03, isradipine, The metabolism of Cyproterone acetate can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The serum concentration of Difluocortolone can be increased when it is combined with Cyproterone acetate.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be decreased when combined with Cyproterone acetate.]
[C02DB01, dihydralazine, The metabolism of Dihydralazine can be increased when combined with Cyproterone acetate.]
[C04AE04, dihydroergocristine, The metabolism of Dihydroergocristine can be decreased when combined with Cyproterone acetate.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be decreased when combined with Cyproterone acetate.]
[J05AE08, atazanavir, The serum concentration of Cyproterone acetate can be increased when it is combined with Atazanavir.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Cyproterone acetate is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Cyproterone acetate can be decreased when combined with Diltiazem.]
[N03AG05, progabide, The metabolism of Cyproterone acetate can be increased when combined with Progabide.]
[N06BC02, propentofylline, The metabolism of Propentofylline can be increased when combined with Cyproterone acetate.]
[J01CE03, propicillin, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Propicillin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Cyproterone acetate is combined with Proparacaine.]
[R03DA03, proxyphylline, The metabolism of Proxyphylline can be increased when combined with Cyproterone acetate.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Cyproterone acetate is combined with Diphenhydramine.]
[B01AC07, dipyridamole, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Dipyridamole.]
[B01AD10, drotrecogin alfa, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Drotrecogin alfa.]
[A03FA02, cisapride, The metabolism of Cisapride can be decreased when combined with Cyproterone acetate.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be decreased when combined with Cyproterone acetate.]
[C01BA03, disopyramide, The metabolism of Disopyramide can be increased when combined with Cyproterone acetate.]
[S02AA12, rifamycin SV, The metabolism of Cyproterone acetate can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Cyproterone acetate can be increased when combined with Rifapentine.]
[N07XX02, riluzole, The metabolism of Riluzole can be increased when combined with Cyproterone acetate.]
[N01BB09, ropivacaine, The metabolism of Ropivacaine can be increased when combined with Cyproterone acetate.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be decreased when combined with Cyproterone acetate.]
[A04AD12, aprepitant, The serum concentration of Cyproterone acetate can be decreased when it is combined with Aprepitant.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be decreased when combined with Cyproterone acetate.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be increased when combined with Cyproterone acetate.]
[A03FA03, domperidone, The metabolism of Domperidone can be increased when combined with Cyproterone acetate.]
[N06AA12, doxepin, The metabolism of Doxepin can be increased when combined with Cyproterone acetate.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be decreased when combined with Cyproterone acetate.]
[J01AA02, doxycycline, The serum concentration of Cyproterone acetate can be decreased when it is combined with Doxycycline.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be decreased when combined with Cyproterone acetate.]
[H01AA01, corticotropin, The serum concentration of Corticotropin can be increased when it is combined with Cyproterone acetate.]
[J01MA05, temafloxacin, The metabolism of Temafloxacin can be increased when combined with Cyproterone acetate.]
[J01CA17, temocillin, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Temocillin.]
[D01BA02, terbinafine, The metabolism of Terbinafine can be increased when combined with Cyproterone acetate.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be decreased when combined with Cyproterone acetate.]
[N03AX11, topiramate, The metabolism of Cyproterone acetate can be increased when combined with Topiramate.]
[J01AA12, tigecycline, The serum concentration of Cyproterone acetate can be decreased when it is combined with Tigecycline.]
[B01AC18, triflusal, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Triflusal.]
[H02CA01, trilostane, The serum concentration of Trilostane can be increased when it is combined with Cyproterone acetate.]
[C05CA04, troxerutin, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Troxerutin.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be decreased when combined with Cyproterone acetate.]
[C08CA12, mepirodipine, The metabolism of Cyproterone acetate can be decreased when combined with Barnidipine.]
[N05CF02, zolpidem, The metabolism of Zolpidem can be increased when combined with Cyproterone acetate.]
[N03AX15, zonisamide, The metabolism of Cyproterone acetate can be increased when combined with Zonisamide.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Cyproterone acetate.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Cyproterone acetate.]
[N05AX11, zotepine, The metabolism of Zotepine can be increased when combined with Cyproterone acetate.]
[B01AD03, anistreplase, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Anistreplase.]
[N02CA02, ergotamine, The metabolism of Cyproterone acetate can be decreased when combined with Ergotamine.]
[S01AA17, erythromycin, The metabolism of Cyproterone acetate can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, The metabolism of Cyproterone acetate can be increased when combined with Estazolam.]
[H05BX01, cinacalcet, The metabolism of Cinacalcet can be increased when combined with Cyproterone acetate.]
[G03CA03, estradiol, The metabolism of Estradiol can be increased when combined with Cyproterone acetate.]
[G03CA57, estrogens, conjugated (USP), The metabolism of Conjugated estrogens can be increased when combined with Cyproterone acetate.]
[R03BA09, fluticasone furoate, The serum concentration of Fluticasone furoate can be increased when it is combined with Cyproterone acetate.]
[R03BA05, fluticasone, The serum concentration of Fluticasone can be increased when it is combined with Cyproterone acetate.]
[N03AD01, ethosuximide, The metabolism of Cyproterone acetate can be increased when combined with Ethosuximide.]
[N03AB01, ethotoin, The metabolism of Cyproterone acetate can be increased when combined with Ethotoin.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Cyproterone acetate is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Cyproterone acetate is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Cyproterone acetate is combined with Etidocaine.]
[L01CB01, etoposide, The metabolism of Etoposide can be increased when combined with Cyproterone acetate.]
[D05BB01, etretinate, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Etretinate.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Cyproterone acetate.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Cyproterone acetate.]
[R06AX12, terfenadine, The metabolism of Cyproterone acetate can be decreased when combined with Terfenadine.]
[N06AB08, fluvoxamine, The metabolism of Fluvoxamine can be increased when combined with Cyproterone acetate.]
[C01BB03, tocainide, The metabolism of Tocainide can be increased when combined with Cyproterone acetate.]
[A05AA01, chenodeoxycholic acid, The therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Cyproterone acetate.]
[D11AX24, deoxycholic acid, The therapeutic efficacy of Deoxycholic acid can be decreased when used in combination with Cyproterone acetate.]
[B05AA05, dextran, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Dextran.]
[P02CA03, albendazole, The metabolism of Albendazole can be increased when combined with Cyproterone acetate.]
[N03AX26, fenfluramine, The metabolism of Fenfluramine can be increased when combined with Cyproterone acetate.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Cyproterone acetate.]
[B01AD05, plasmin, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Fibrinolysin.]
[C01BC04, flecainide, The metabolism of Flecainide can be increased when combined with Cyproterone acetate.]
[J01CF05, floxacillin, The metabolism of Cyproterone acetate can be increased when combined with Flucloxacillin.]
[J02AC01, fluconazole, The bioavailability of Cyproterone acetate can be increased when combined with Fluconazole.]
[H02AA02, fludrocortisone, The serum concentration of Fludrocortisone can be increased when it is combined with Cyproterone acetate.]
[D07XB01, flumethasone, The serum concentration of Flumethasone can be increased when it is combined with Cyproterone acetate.]
[N07CA03, flunarizine, The metabolism of Flunarizine can be increased when combined with Cyproterone acetate.]
[D07AC08, fluocinonide, The serum concentration of Fluocinonide can be increased when it is combined with Cyproterone acetate.]
[H02AB03, fluocortolone, The serum concentration of Fluocortolone can be increased when it is combined with Cyproterone acetate.]
[V03AZ01, ethanol, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Ethanol.]
[S01CB05, fluorometholone, The serum concentration of Fluorometholone can be increased when it is combined with Cyproterone acetate.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be increased when combined with Cyproterone acetate.]
[N06AB03, fluoxetine, The metabolism of Fluoxetine can be increased when combined with Cyproterone acetate.]
[L02BB01, flutamide, The metabolism of Flutamide can be increased when combined with Cyproterone acetate.]
[L01BC03, tegafur, The metabolism of Tegafur can be increased when combined with Cyproterone acetate.]
[J05AE10, darunavir, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Darunavir.]
[N05CF04, eszopiclone, The metabolism of Eszopiclone can be decreased when combined with Cyproterone acetate.]
[N03AA04, barbexaclone, The metabolism of Cyproterone acetate can be increased when combined with Barbexaclone.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be increased when combined with Cyproterone acetate.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be decreased when combined with Cyproterone acetate.]
[C01CA21, cafedrine, The metabolism of Cafedrine can be increased when combined with Cyproterone acetate.]
[A10BJ02, liraglutide, The therapeutic efficacy of Liraglutide can be decreased when used in combination with Cyproterone acetate.]
[J05AG04, etravirine, The metabolism of Cyproterone acetate can be increased when combined with Etravirine.]
[N03AD03, methsuximide, The metabolism of Cyproterone acetate can be increased when combined with Methsuximide.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be decreased when used in combination with Cyproterone acetate.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be decreased when used in combination with Cyproterone acetate.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be decreased when used in combination with Cyproterone acetate.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be decreased when combined with Cyproterone acetate.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Cyproterone acetate.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be increased when combined with Cyproterone acetate.]
[B01AA12, fluindione, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Fluindione.]
[D01BA01, griseofulvin, The metabolism of Cyproterone acetate can be increased when combined with Griseofulvin.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Cyproterone acetate.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Cyproterone acetate.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be decreased when combined with Cyproterone acetate.]
[S01XA14, heparin, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Heparin.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be decreased when combined with Cyproterone acetate.]
[N05CA16, hexobarbital, The metabolism of Cyproterone acetate can be increased when combined with Hexobarbital.]
[C08CA10, nilvadipine, The metabolism of Cyproterone acetate can be decreased when combined with Nilvadipine.]
[S02BA01, hydrocortisone, The serum concentration of Hydrocortisone can be increased when it is combined with Cyproterone acetate.]
[J04AB04, rifabutin, The metabolism of Cyproterone acetate can be increased when combined with Rifabutin.]
[B05CB02, sodium citrate, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Sodium citrate.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Cyproterone acetate.]
[N06AA02, imipramine, The metabolism of Imipramine can be increased when combined with Cyproterone acetate.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Cyproterone acetate.]
[R01AD07, tixocortol, The serum concentration of Tixocortol can be increased when it is combined with Cyproterone acetate.]
[M03BX02, tizanidine, The metabolism of Tizanidine can be increased when combined with Cyproterone acetate.]
[N06AX17, milnacipran, The metabolism of Cyproterone acetate can be decreased when combined with Milnacipran.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Cyproterone acetate is combined with Articaine.]
[A10BH01, sitagliptin, The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Cyproterone acetate.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Cyproterone acetate.]
[N05CH02, ramelteon, The metabolism of Ramelteon can be increased when combined with Cyproterone acetate.]
[A10BH02, vildagliptin, The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Cyproterone acetate.]
[C10AA06, cerivastatin, The metabolism of Cyproterone acetate can be increased when combined with Cerivastatin.]
[L01XX35, anagrelide, The metabolism of Anagrelide can be increased when combined with Cyproterone acetate.]
[J05AB13, penciclovir, The metabolism of Penciclovir can be increased when combined with Cyproterone acetate.]
[J04AC01, isoniazid, The metabolism of Cyproterone acetate can be decreased when combined with Isoniazid.]
[A10BJ01, exenatide, Exenatide can cause a decrease in the absorption of Cyproterone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[D10BA01, isotretinoin, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Isotretinoin.]
[B01AE06, bivalirudin, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Bivalirudin.]
[L04AC07, tocilizumab, The metabolism of Cyproterone acetate can be increased when combined with Tocilizumab.]
[B01AC22, prasugrel, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Prasugrel.]
[J02AB02, ketoconazole, The metabolism of Cyproterone acetate can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Cyproterone acetate can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, The metabolism of Olanzapine can be increased when combined with Cyproterone acetate.]
[V03AC03, deferasirox, The metabolism of Cyproterone acetate can be increased when combined with Deferasirox.]
[N03AX18, lacosamide, The metabolism of Cyproterone acetate can be increased when combined with Lacosamide.]
[J01CA11, amdinocillin, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Amdinocillin.]
[J01CA08, amdinocillin pivoxil, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Pivmecillinam.]
[S02DA01, lidocaine, The metabolism of Lidocaine can be increased when combined with Cyproterone acetate.]
[N06BA13, armodafinil, The metabolism of Cyproterone acetate can be increased when combined with Armodafinil.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Cyproterone acetate.]
[N05BA06, lorazepam, The metabolism of Cyproterone acetate can be increased when combined with Lorazepam.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Cyproterone acetate.]
[J01AA04, lymecycline, The serum concentration of Cyproterone acetate can be decreased when it is combined with Lymecycline.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be decreased when combined with Cyproterone acetate.]
[V04CC02, magnesium sulfate, The metabolism of Cyproterone acetate can be increased when combined with Magnesium sulfate.]
[L01EA03, nilotinib, The metabolism of Cyproterone acetate can be decreased when combined with Nilotinib.]
[N06AA21, maprotiline, The metabolism of Maprotiline can be increased when combined with Cyproterone acetate.]
[N05BA03, medazepam, The metabolism of Cyproterone acetate can be increased when combined with Medazepam.]
[B01AB06, nadroparin, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Dalteparin.]
[N05CH01, melatonin, The metabolism of Melatonin can be increased when combined with Cyproterone acetate.]
[N02AB02, meperidine, The metabolism of Meperidine can be decreased when combined with Cyproterone acetate.]
[N03AB04, mephenytoin, The metabolism of Mephenytoin can be increased when combined with Cyproterone acetate.]
[N03AA01, mephobarbital, The metabolism of Cyproterone acetate can be increased when combined with Methylphenobarbital.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Cyproterone acetate is combined with Mepivacaine.]
[L02BG01, aminoglutethimide, The metabolism of Cyproterone acetate can be increased when combined with Aminoglutethimide.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be decreased when used in combination with Cyproterone acetate.]
[J01AA05, methacycline, The serum concentration of Cyproterone acetate can be decreased when it is combined with Metacycline.]
[N03AA30, metharbital, The metabolism of Cyproterone acetate can be increased when combined with Metharbital.]
[H03BB02, methimazole, The metabolism of Cyproterone acetate can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, The metabolism of Pemetrexed can be increased when combined with Cyproterone acetate.]
[N05CA15, methohexital, The metabolism of Cyproterone acetate can be increased when combined with Methohexital.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be decreased when combined with Cyproterone acetate.]
[V04CG05, methylene blue, The metabolism of Methylene blue can be increased when combined with Cyproterone acetate.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be increased when combined with Cyproterone acetate.]
[H02AB04, methylprednisolone, The serum concentration of Methylprednisolone can be increased when it is combined with Cyproterone acetate.]
[D07AC14, methylprednisolone aceponate, The serum concentration of Methylprednisolone aceponate can be increased when it is combined with Cyproterone acetate.]
[N03AF03, rufinamide, The metabolism of Cyproterone acetate can be increased when combined with Rufinamide.]
[N02CA04, methysergide, The metabolism of Methysergide can be decreased when combined with Cyproterone acetate.]
[A03FA01, metoclopramide, The metabolism of Metoclopramide can be increased when combined with Cyproterone acetate.]
[V04CD01, metyrapone, The metabolism of Cyproterone acetate can be increased when combined with Metyrapone.]
[C01BB02, mexiletine, The metabolism of Mexiletine can be increased when combined with Cyproterone acetate.]
[J01CA10, mezlocillin, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Mezlocillin.]
[N06AX03, mianserin, The metabolism of Mianserin can be increased when combined with Cyproterone acetate.]
[S02AA13, miconazole, The metabolism of Cyproterone acetate can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be increased when combined with Cyproterone acetate.]
[B01AB07, parnaparin, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Parnaparin.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Cyproterone acetate.]
[G03XB01, mifepristone, The therapeutic efficacy of Mifepristone can be decreased when used in combination with Cyproterone acetate.]
[B01AB10, tinzaparin, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Tinzaparin.]
[J01AA08, minocycline, The serum concentration of Cyproterone acetate can be decreased when it is combined with Minocycline.]
[L01XX23, mitotane, The metabolism of Cyproterone acetate can be increased when combined with Mitotane.]
[C01BD01, amiodarone, The metabolism of Cyproterone acetate can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be increased when combined with Cyproterone acetate.]
[B02BX05, eltrombopag, The metabolism of Eltrombopag can be increased when combined with Cyproterone acetate.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be increased when combined with Cyproterone acetate.]
[L04AA06, mycophenolic acid, The serum concentration of Cyproterone acetate can be decreased when it is combined with Mycophenolic acid.]
[N05CA02, amobarbital, The metabolism of Cyproterone acetate can be increased when combined with Amobarbital.]
[N03AB05, fosphenytoin, The metabolism of Cyproterone acetate can be increased when combined with Fosphenytoin.]
[J01CA04, amoxicillin, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Amoxicillin.]
[N04BC04, ropinirole, The metabolism of Ropinirole can be increased when combined with Cyproterone acetate.]
[J01CF06, nafcillin, The metabolism of Cyproterone acetate can be increased when combined with Nafcillin.]
[V03AB15, naloxone, The metabolism of Cyproterone acetate can be decreased when combined with Naloxone.]
[M02AA12, naproxen, The metabolism of Naproxen can be increased when combined with Cyproterone acetate.]
[A10BG01, troglitazone, The therapeutic efficacy of Troglitazone can be decreased when used in combination with Cyproterone acetate.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cyproterone acetate.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be decreased when combined with Cyproterone acetate.]
[A10BX02, repaglinide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Cyproterone acetate.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Cyproterone acetate.]
[S01AA19, ampicillin, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Ampicillin.]
[N06AX23, desvenlafaxine, The metabolism of Cyproterone acetate can be decreased when combined with Desvenlafaxine.]
[C08CA04, nicardipine, The metabolism of Cyproterone acetate can be decreased when combined with Nicardipine.]
[C08CA05, nifedipine, The metabolism of Nifedipine can be increased when combined with Cyproterone acetate.]
[N05CD02, nitrazepam, The metabolism of Cyproterone acetate can be increased when combined with Nitrazepam.]
[N05CF03, zaleplon, The metabolism of Cyproterone acetate can be increased when combined with Zaleplon.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be decreased when combined with Cyproterone acetate.]
[C02KX01, bosentan, The serum concentration of Cyproterone acetate can be decreased when it is combined with Bosentan.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Cyproterone acetate.]
[B01AB08, reviparin, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Reviparin.]
[H01CB02, octreotide, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Octreotide.]
[A02BC01, omeprazole, The metabolism of Cyproterone acetate can be increased when combined with Omeprazole.]
[B01AD07, reteplase, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Reteplase.]
[B01AD09, ancrod, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Ancrod.]
[J01CF04, oxacillin, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Oxacillin.]
[S01AA04, oxytetracycline, The serum concentration of Cyproterone acetate can be decreased when it is combined with Oxytetracycline.]
[N05AH05, asenapine, The metabolism of Asenapine can be increased when combined with Cyproterone acetate.]
[B01AB09, danaparoid, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Danaparoid.]
[N05CC05, paraldehyde, The metabolism of Cyproterone acetate can be increased when combined with Paraldehyde.]
[H02AB05, paramethasone, The serum concentration of Paramethasone can be increased when it is combined with Cyproterone acetate.]
[S01AA14, penicillin G, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Benzylpenicillin.]
[J01CE09, penicillin G procaine, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Procaine benzylpenicillin.]
[J01CE02, penicillin V, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Phenoxymethylpenicillin.]
[N05CA01, pentobarbital, The metabolism of Cyproterone acetate can be increased when combined with Pentobarbital.]
[C04AD03, pentoxifylline, The metabolism of Pentoxifylline can be increased when combined with Cyproterone acetate.]
[N05AB03, perphenazine, The metabolism of Perphenazine can be increased when combined with Cyproterone acetate.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be increased when combined with Cyproterone acetate.]
[A10BA01, phenformin, The therapeutic efficacy of Phenformin can be decreased when used in combination with Cyproterone acetate.]
[B01AA02, phenindione, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Phenindione.]
[N03AA02, phenobarbital, The metabolism of Cyproterone acetate can be increased when combined with Phenobarbital.]
[B01AA04, phenprocoumon, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Phenprocoumon.]
[M02AA01, phenylbutazone, The metabolism of Cyproterone acetate can be increased when combined with Phenylbutazone.]
[N03AB02, phenytoin, The metabolism of Cyproterone acetate can be increased when combined with Phenytoin.]
[L01XF02, alitretinoin, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Alitretinoin.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be decreased when combined with Cyproterone acetate.]
[N05AG02, pimozide, The metabolism of Pimozide can be increased when combined with Cyproterone acetate.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Cyproterone acetate.]
[J01CA12, piperacillin, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Piperacillin.]
[J05AE01, saquinavir, The metabolism of Cyproterone acetate can be decreased when combined with Saquinavir.]
[J01MA11, grepafloxacin, The metabolism of Grepafloxacin can be increased when combined with Cyproterone acetate.]
[J01CA02, pivampicillin, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Pivampicillin.]
[J05AG02, delavirdine, The metabolism of Cyproterone acetate can be decreased when combined with Delavirdine.]
[B01AC13, abciximab, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Abciximab.]
[D05AX05, tazarotene, The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Tazarotene.]
[S01XA13, alteplase, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Alteplase.]
[A10BG02, rosiglitazone, The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Cyproterone acetate.]
[A03AE01, alosetron, The metabolism of Alosetron can be increased when combined with Cyproterone acetate.]
[J05AE03, ritonavir, The serum concentration of Cyproterone acetate can be decreased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Cyproterone acetate.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Cyproterone acetate.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be increased when combined with Cyproterone acetate.]
[S03BA02, prednisolone, The serum concentration of Prednisolone can be increased when it is combined with Cyproterone acetate.]
[H02AB07, prednisone, The serum concentration of Prednisone can be increased when it is combined with Cyproterone acetate.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Cyproterone acetate is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Primaquine can be increased when combined with Cyproterone acetate.]
[N03AA03, primidone, The metabolism of Cyproterone acetate can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Cyproterone acetate can be increased when combined with Probenecid.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Cyproterone acetate is combined with Procaine.]
[C10AB05, fenofibrate, The metabolism of Fenofibrate can be decreased when combined with Cyproterone acetate.]
[N05AA03, promazine, The metabolism of Promazine can be increased when combined with Cyproterone acetate.]
[C01BC03, propafenone, The metabolism of Propafenone can be increased when combined with Cyproterone acetate.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be decreased when combined with Cyproterone acetate.]
[C07AA05, propranolol, The metabolism of Propranolol can be increased when combined with Cyproterone acetate.]
[B01AC09, epoprostenol, The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Epoprostenol.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Cyproterone acetate.]
[C01BA01, quinidine, The metabolism of Quinidine can be decreased when combined with Cyproterone acetate.]
[P01BC01, quinine, The metabolism of Quinine can be increased when combined with Cyproterone acetate.]
[A02BA02, ranitidine, The metabolism of Ranitidine can be increased when combined with Cyproterone acetate.]
[J04AB02, rifampin, The metabolism of Cyproterone acetate can be increased when combined with Rifampicin.]
[J01AA09, rolitetracycline, The serum concentration of Cyproterone acetate can be decreased when it is combined with Rolitetracycline.]
[N05CA06, secobarbital, The metabolism of Cyproterone acetate can be increased when combined with Secobarbital.]
[N04BD01, selegiline, The bioavailability of Selegiline can be increased when combined with Cyproterone acetate.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Cyproterone acetate.]
[N03AG01, valproic acid, The metabolism of Cyproterone acetate can be increased when combined with Valproic acid.]
[D07AB02, hydrocortisone butyrate, The serum concentration of Hydrocortisone butyrate can be increased when it is combined with Cyproterone acetate.]
[A05AA02, ursodiol, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Cyproterone acetate.]
